FUTURE SCRIPTS

Please complete ALL information below and fax your request to 1-888-671-5285

Verzenio™ Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
❑ Check if **generic substitution** is acceptable ❑ Check if request is for **continuation of therapy**	Directions for Use:	

Clinical Information (required)

Select the diagnosis below:

❑ Breast cancer

❑ Other diagnosis: _____ ICD-10 Code(s): _____

Clinical Information:

Does the patient have advanced or metastatic breast cancer? ❑ **Yes** ❑ **No**

Does the patient have hormone-receptor (HR)-positive disease? ❑ **Yes** ❑ **No**

Does the patient have human epidermal growth factor receptor 2 (HER2)-negative disease? ❑ **Yes** ❑ **No**

Is the patient a postmenopausal woman? ❑ **Yes** ❑ **No**

Will Verzenio be used in combination with an aromatase inhibitor (e.g., Arimidex [anastrozole], Aromasin [exemestane], Femara [letrozole])? ❑ **Yes** ❑ **No**

Will Verzenio be used in combination with Faslodex (fulvestrant)? ❑ **Yes** ❑ **No**

Has the patient experienced disease progression following endocrine therapy? ❑ **Yes** ❑ **No**

Will Verzenio be used as monotherapy? ❑ **Yes** ❑ **No**

Has the patient received at least one prior chemotherapy regimen? ❑ **Yes** ❑ **No**

Is Verzenio prescribed by or in consultation with an oncologist? ❑ **Yes** ❑ **No**

Reauthorization:

Does the patient show evidence of progressive disease while on Verzenio therapy? ❑ **Yes** ❑ **No**

Quantity Limit Requests:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

❑ Titration or loading dose purposes

❑ Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)

❑ Requested strength/dose is not commercially available

❑ Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: This request may be denied unless all required information is received.

Office use only: Verzenio_FSP_2019Mar-W